With Limits Created By China's New Pharmacopoeia, What's Next For Vaccine Manufacturers?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China is expected to be the world's largest vaccine market by 2020, and every vaccine maker is trying to increase their presence to gain market share. However, the new Chinese Pharmacopoeia might put these efforts to an end and almost all vaccines from multinational companies may have to withdraw from China if they fail to comply with new standards
You may also be interested in...
Knowing Regs Key as China Gets Tougher on GMP Inspections
China FDA has significantly beefed up inspections of foreign drug manufacturing sites, underscoring the agency’s increasing assertiveness in regulatory enforcement. Staying out of trouble requires staying on top of local regulatory updates, regulatory experts say.
China’s Best Shot: GSK, Novartis Gear Up For Vaccine Prime Time
With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.
Merck Expands Deal With Chinese Vaccines Firm As MNCs Look To Recover From China Pharmacopeia Issue
Merck is including its vaccine distribution partner Chongqing Zhifei in its development plan for at least two vaccines in China, while global firms regain a footing after new standards in the Chinese Pharmacopeia stilted their market growth.